Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | The use of AI for analyzing genetic and molecular data in CLL

Andreas Agathangelidis • 6 Oct 2022
ERIC 2022
Chronic Lymphocytic Leukemia Leukemia

Andreas Agathangelidis, PhD, Center for Research and Technology Hellas, Thermi, Greece, discusses the emergent use of artificial intelligence (AI) in chronic lymphocytic leukemia (CLL). Dr Agathangelidis explains how applying a different approach in analyzing molecular data could help generate novel findings in CLL. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andreas Agathangelidis

1:24
The interplay between genetic and environmental factors in MBL
Andreas Agathangelidis • 6 Oct 2022
0:58
Updates on the ERIC recommendations for immunoglobulin gene sequence analysis in CLL
Andreas Agathangelidis • 6 Oct 2022
0:53
Clinical significance of Ig gene mutations in CLL
Andreas Agathangelidis • 6 Oct 2022
2:49
The past and present of immunoglobulin genes in CLL
Andreas Agathangelidis • 29 Sep 2020

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals